Rius Medical

Dear investors,

Biologics have dominated the pharmaceutical industry for years. In 2016, eight of the ten top global best-selling drugs were biologics. This rise of biologics is set to continue, according to a new report by European Pharmaceutical Review www. Biologics are forecast to have $120 billion greater sales than small molecules by 2027.

Nonetheless the tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic profiles of therapeutic agents and has been applied in the clinic for over 33 years.

However, Pegylated enzymes are associated with severe immune-mediated adverse reactions and anaphylaxis! Effective treatments against oncology and genetic diseases; Rius Medical is ideally positioned to make a difference for those patients with enormous unmet medical need that cannot be helped today. That’s right, improved Biologics for effective treatments (i.e. enzyme-biologics) against oncology and genetic diseases is the primary focus of Rius Medical. [More info on the PDF download]

Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Rius Medical solves the scientific and technical hurdles blocking access to life changing protein therapeutics (enzyme or antigen biologics) by “reprogramming stem cells” into cell therapies.

Many thanks and warmest regards,

Denis

Denis Demarais

Founder and CEO

Email: denisdemarais@riusmedical.de

Dear investors,

There is no question about the incredible clinical impact cell therapies can have on the lives of patients. For drug delivery using red blood cells: Progress in clinical development is with providers like Erytech Pharma addressing cancer, Orphan Technologies addressing rare disease of metabolism MNGIE, Rubius Therapeutics addressing rare disease of metabolism Phenylketonuria and Anokion addressing autoimmune diseases like type 1 diabetes, celiac disease and Multiple Sclerosis.

However, this impact is the result of innovation that does not equate to a simple, straightforward commercialisation process. The commercialisation and management requirements of these treatments are just as complex as their innovative science. That’s because traditional production model has all the cells made by hand in batches, by highly trained scientists sitting in a clean room. That’s not scalable.

Rius Medical approach with TECHNOLOGY TRANSFER as provider engagement is a significant understatement in the context of cell therapies. Unlike when dealing with traditional pharmaceutical products, providers need a much greater level of support in order to successfully operationalize and provide cell therapies, and they look to manufacturers for help. For example April 2022 Erytech Pharma made a collaboration agreement with CDMO Catalent www. The "Rius Medical upgrade" allows providers to bring new products to market faster www.

Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Keep in mind that you the investor in Rius Medical shall receive 20% refund on investment from the German Ministry for Economic Affairs and Climate Protection (BMWK) www. Rius Medical solves the scientific and technical hurdles blocking access to life changing protein therapeutics (enzyme or antigen biologics) by “reprogramming stem cells” into cell therapies.

Many thanks and warmest regards,

Denis

Denis Demarais
Founder and CEO

Email: denisdemarais@riusmedical.de